welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two Years with Nonsense Mutation Duchenne Muscular Dystrophy
PTC Therapeutics, Inc. today announced the presentation of data from the Translarna (ataluren) Phase II Study 030 demonstrating that the safety and pharmacokinetic profile of Translarna in children from two to five years with nonsense mutation Duchenne muscular dystrophy (nmDMD) was consistent with that for older children.1 Importantly, the data also showed that treatment with Translarna resulted in improvements in timed function tests and the North Star Ambulatory Assessment from baseline at weeks 28 and 52, with mean changes showing as much as a 25 percent improvement after one year.
The data at 28 weeks formed the basis of the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to expand the current indication of Translarna to include nmDMD ambulatory children from two to five years of age.2 The data was presented at the International Congress on Neuromuscular Diseases in Vienna.
rareRelated
-
Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyThis study is a long-term study of atalu...
-
An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular DystrophyThis study is an open-label extension to...
-
Study of Ataluren in >=2 to <5 Year-Old Males With Duchenne Muscular DystrophyThis is a Phase 2, multiple-dose, open-l...
-
Study of Eteplirsen in DMD PatientsThe main objective of this study is to p...
-
Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular DystrophyThis study is being performed as a post-...
-
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular DystrophyThis study is single arm, single center ...
-
Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular DystrophyWhile it has been known for many years t...
-
New Analyses of Translarna™ (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology...PTC Therapeutics, Inc. today announced t...
-
PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical TrialPTC Therapeutics, Inc. is seeking pa...
-
Safety and Tolerability of Ataluren in a Phase 3 Study of Patients with Nonsense Mutation Duchenne Muscular Dystroph...Objective: Examine the safety/tolerabil...
-
Boy with muscular dystrophy writes heartfelt note to Scottish leaderMichael Young, 9, wrote a letter to Scot...
-
Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggestResults of the Phase 2 MoveDMD trial sho...
